Effects of a milk oligosaccharide biosimilar on fecal characteristics, microbiota, and bile acid, calprotectin, and immunoglobulin concentrations of healthy adult dogs treated with metronidazole
Journal of Animal Science · 2023
DOI: 10.1093/jas/skad011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Animal Science, 2023. Verfasst von Sara E Belchik und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Cat Diseases, Gastrointestinal Microbiome, Dog Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
In recent dog and cat experiments, a novel milk oligosaccharide biosimilar (GNU100) positively modulated fecal microbiota and metabolite profiles, suggesting benefits to gastrointestinal health. The objective of this study was to investigate the effects of GNU100 on the fecal characteristics, microbiota, and bile acid (BA) concentrations of healthy adult dogs treated with antibiotics. Twelve healthy adult female dogs (mean age: 3.74 ± 2.4 yr) were used in an 8-wk crossover design study (dogs underwent both treatments). All dogs were fed a control diet during a 2-wk baseline, then randomly allotted to 1 of 2 treatments (diet only or diet + 1% GNU100) for another 6 wk. From weeks 2 to 4, dogs were orally administered metronidazole (20 mg/kg BW) twice daily. Fecal scores were recorded daily and fresh fecal samples were collected at weeks 2, 4, 5, 6, and 8 for measurement of pH, dry matter, microbiota populations, and BA, immunoglobulin A, and calprotectin concentrations. On weeks 0, 4, and 8, blood samples were collected for serum chemistry and hematology analysis. All data were analyzed as repeated measures using the Mixed Models procedure of SAS version 9.4, with significance considered P < 0.05. Metronidazole increased (P < 0.0001) fecal scores (looser stools) and modified (P < 0.05) fecal microbiota and BA profiles. Using qPCR, metronidazole reduced fecal Blautia, Fusobacterium, Turicibacter, Clostridium hiranonis, and Faecalibacterium abundances, and increased fecal Streptococcus and Escherichia coli abundances. DNA sequencing analysis demonstrated that metronidazole reduced microbial alpha diversity and influenced the relative abundance of 20 bacterial genera and families. Metronidazole also increased primary BA and reduced secondary BA concentrations. Most antibiotic-induced changes returned to baseline by week 8. Fecal scores were more stable (P = 0.01) in GNU100-fed dogs than controls after antibiotic administration. GNU100 also influenced fecal microbiota and BA profiles, reducing (P < 0.05) the influence of metronidazole on microbial alpha diversity and returning some fecal microbiota and secondary BA to baseline levels at a quicker (P < 0.05) rate than controls. In conclusion, our results suggest that GNU100 supplementation provides benefits to dogs treated with antibiotics, providing more stable fecal scores, maintaining microbial diversity, and allowing for quicker recovery of microbiota and secondary BA profiles which play an essential role in gut health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Animal Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
- Gnubiotics Sciences, Route de la Corniche 6, Epalinges, Switzerland.
- Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, Texas A&M University, College Station, TX, USA.
- Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
- Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
ORCID-Profile: Patricia M Oba, Kelly S Swanson
Zitieren
APA
Belchik, S. E., Oba, P. M., Wyss, R., Asare, P. T., Vidal, S., Miao, Y., Adesokan, Y., Suchodolski, J. S., & Swanson, K. S. (2023). Effects of a milk oligosaccharide biosimilar on fecal characteristics, microbiota, and bile acid, calprotectin, and immunoglobulin concentrations of healthy adult dogs treated with metronidazole. Journal of Animal Science. https://doi.org/10.1093/jas/skad011
Vancouver
Belchik SE, Oba PM, Wyss R, Asare PT, Vidal S, Miao Y, et al. Effects of a milk oligosaccharide biosimilar on fecal characteristics, microbiota, and bile acid, calprotectin, and immunoglobulin concentrations of healthy adult dogs treated with metronidazole. Journal of Animal Science. 2023. doi:10.1093/jas/skad011
BibTeX
@article{Belchik2023,
author = {Belchik, Sara E and Oba, Patricia M and Wyss, Romain and Asare, Paul T and Vidal, Sara and Miao, Yong and Adesokan, Yemi and Suchodolski, Jan S and Swanson, Kelly S},
title = {Effects of a milk oligosaccharide biosimilar on fecal characteristics, microbiota, and bile acid, calprotectin, and immunoglobulin concentrations of healthy adult dogs treated with metronidazole},
journal = {Journal of Animal Science},
year = {2023},
doi = {10.1093/jas/skad011}
}
EUVIMED